Nazanin Farahbakhsh, Deepak Sharma, Somaye Fatahi, Mobina Fathi, Kimia Vakili, Niloofar Deravi, Zohreh Tutunchian, Elahe Ahsan, Shirin Yaghoobpoor, Seyed Ahmad Tabatabaii
Effects of Vitamin D and E Supplementation on Prevention of Bronchopulmonary Dysplasia (BPD) in Premature Neonates: A Systematic Review and Meta-Analysis
Current pediatric reviews
mitochondrial dysfunction metabolic abnormalities acknowledged significant factors onset neurodegenerative disorders parkinsons disease pd alzheimers disease ad research demonstrated use combined metabolic activators cma may alleviate metabolic dysfunctions stimulate mitochondrial metabolism therefore use cma could potentially effective therapeutic strategy slow halt progression pd ad cmas include substances glutathione precursors lserine nacetyl cysteine nad precursor nicotinamide riboside lcarnitine tartrate tested effect two different formulations including cma1 nicotinamide riboside lserine nacetyl cysteine lcarnitine tartrate cma2 nicotinamide lserine nacetyl cysteine lcarnitine tartrate well individual components animal models ad pd assessed brain liver tissues pathological changes immunohistochemical markers additionally case pd performed behavioral tests measured responses apomorphineinduced rotations histological analysis showed administration cma1 cma2 formulations led improvements hyperemia degeneration necrosis neurons ad pd models moreover administration cma2 showed superior effect compared cma1 corroborated immunohistochemical data indicated reduction immunoreactivity neurons additionally notable metabolic enhancements liver tissues observed using formulations pd rat models administration formulations positively influenced behavioral functions animals findings suggest administration cma1 cma2 markedly enhanced metabolic behavioral outcomes aligning neurohistological observations findings underscore promise cma2 administration effective therapeutic strategy enhancing metabolic parameters cognitive function ad pd patients